Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 43 Records) |
| Query Trace: Thromboembolism and VKORC1[original query] |
|---|
| Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011 Sep 118 (11): 3163-71. Gong Inna Y, Tirona Rommel G, Schwarz Ute I, Crown Natalie, Dresser George K, Larue Samantha, Langlois Nicole, Lazo-Langner Alejandro, Zou Guangyong, Roden Dan M, Stein C Michael, Rodger Marc, Carrier Marc, Forgie Melissa, Wells Philip S, Kim Richard |
| [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage]. Terapevticheski? arkhiv 2011 83 (6): 59-65. Vorob'eva N M, Panchenko E P, Dobrovol'ski? A B, Titaeva E V, Khasanova Z B, Konovalova N V, Postnov A Iu, Kirienko A |
| White blood cells contribute to patient-specific warfarin dose for Han Chinese. Chinese medical journal 2012 Jun 125 (11): 1960-3. Zhu Jin, Zheng Wen-Jie, Zhang Wei-Juan, Wang He-Yao, Wang Ch |
| Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients. Thrombosis research 2012 Sep 130 (3): 435-40. Liu Yu, Yang Jie, Xu Qiang, Xu Bin, Gao Lei, Zhang Yuxiao, Zhang Yan, Wang Hongjuan, Lu Caiyi, Zhao Yusheng, Yin To |
| Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. Trials 2012 Dec 13 (1): 1. Carcas AJ, Borobia AM, Velasco M, Abad-Santos F, Díaz MQ, Fernández-Capitán C, Ruiz-Giménez N, Madridano O, Sillero PL |
| The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population. Molecular biology reports 2012 Oct . Silan C, Dogan OT, Silan F, Kukulguven FM, Asgun HF, Ozdemir S, Uludag A, Atik S, Gungor B, Akdur S, Aksulu HE, Ozdemir O |
| Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics 2012 Feb 13 (3): 309-21. Zhang Wei, Zhang Wei-Juan, Zhu Jin, Kong Fan-Cui, Li Yan-Yan, Wang He-Yao, Yang Yuan-Hua, Wang Ch |
| Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model. Thrombosis journal 2013 11 (1): 14. Nshimyumukiza Léon, Duplantie Julie, Gagnon Mathieu, Douville Xavier, Fournier Diane, Lindsay Carmen, Parent Marc, Milot Alain, Giguère Yves, Gagné Christian, Rousseau François, Reinharz Dani |
| The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes. Cardiology 2013 125 (3): 182-91. Tomek Aleš, Ma?oška Václav, Kolá?ová Tereza, Neumann Ji?í, Srámek Martin, Sarbochová Ivana, Táborský Lud?k, Bojar Martin, Goetz Petr, Serebruany Victor |
| A randomized trial of genotype-guided dosing of warfarin. The New England journal of medicine 2013 Dec 369 (24): 2294-303. Pirmohamed Munir, Burnside Girvan, Eriksson Niclas, Jorgensen Andrea L, Toh Cheng Hock, Nicholson Toby, Kesteven Patrick, Christersson Christina, Wahlström Bengt, Stafberg Christina, Zhang J Eunice, Leathart Julian B, Kohnke Hugo, Maitland-van der Zee Anke H, Williamson Paula R, Daly Ann K, Avery Peter, Kamali Farhad, Wadelius Mia, |
| [Personalized drug therapy-directed clinical pharmacology research based on genetic polymorphisms and pharmacokinetics analysis]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2013 133 (10): 1079-85. Hayashi Hide |
| Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm. Pharmacogenetics and genomics 2014 Oct 24 (10): 501-13. Jiménez-Varo Enrique, Cañadas-Garre Marisa, Gutiérrez-Pimentel María J, Calleja-Hernández Miguel |
| Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population. The pharmacogenomics journal 2015 Feb 15 (1): 101-8. Tekola-Ayele F, Adeyemo A, Aseffa A, Hailu E, Finan C, Davey G, Rotimi C N, Newport M |
| [Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2014 Jun 31 (3): 367-71. Lou Ying, Han Lulu, Li Yan, Zhang Xiaoxing, Liu Zhihong, Tang Min, Yu Haiwen, Wang Wei, Xu Jianping, Liu Hong, Li Yis |
| Pharmacogenetics role in the safety of acenocoumarol therapy. Thrombosis and haemostasis 2014 Sep 112 (3): 522-36. Jiménez-Varo E, Cañadas-Garre M, Henriques C I, Pinheiro A M, Gutiérrez-Pimentel M J, Calleja-Hernández M |
| [A randomized controlled study of the VKORC1 and CYP2C9 genotypes in guiding warfarin therapy for pulmonary thromboembolism]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2013 Dec 36 (12): 950-3. Li Jie, Liu Shuang, Yang Jing-hua, Guo Wei, Wang Zeng-zhi, Chen Yong, Wang Sheng-h |
| Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study. Molecular diagnosis & therapy 2014 Dec 18 (6): 675-83. de Oliveira Almeida Vanessa Cristina, Ribeiro Daniel Dias, Gomes Karina Braga, Godard Ana Lúcia Brunial |
| VKORC1 polymorphisms and warfarin maintenance dose in population of Sakha (Yakuts). The International journal of risk & safety in medicine 2015 Nov 27 Suppl 1 S17-8. Chertovskikh Y V, Malova E U, Maksimova N R, Popova N V, Sychev D |
| Comparison of Aspirin and Naoxintong Capsule () with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase. Chinese journal of integrative medicine 2016 Feb . Wang Huan, Zhou Xiao-Kai, Zheng Li-Fan, Wu Xiao-Ying, Chen H |
| Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy. International journal of hematology-oncology and stem cell research 2015 Oct 9 (4): 185-92. Poopak Behzad, Rabieipoor Saghar, Safari Nazila, Naraghi Emadedin, Sheikhsofla Fatemeh, Khosravipoor Gelar |
| Prevalence of common hereditary risk factors for thrombophilia in Somalia and identification of a novel Gln544Arg mutation in coagulation factor V. Journal of thrombosis and thrombolysis 2017 Sep . Abdi Abshir Ali, Osman Abdimaj |
| Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists. Journal of thrombosis and haemostasis : JTH 2017 Aug . Nagler M, Angelillo-Scherrer A, Méan M, Limacher A, Abbal C, Righini M, Beer J H, Osterwalder J, Frauchiger B, Aschwanden M, Matter C M, Kucher N, Cornuz J, Banyai M, Husmann M, Staub D, Mazzolai L, Hugli O, Rodondi N, Aujesky |
| Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2017 Apr . Park Yun Kyung, Lee Mi Ji, Kim Jae Ha, Lee Jin Soo, Park Rae Woong, Kim Gyeong-Moon, Chung Chin-Sang, Lee Kwang Ho, Kim June Soo, Lee Soo-Youn, Bang Oh You |
| The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years. Blood cells, molecules & diseases 2016 Dec . Nowak-Göttl U, Dietrich K, Kruempel A, Geisen C, Mitchell L |
| Frequency of vitamin K oxidoreductase complex subunit-1 (VKORC1) polymorphisms and warfarin dose management in patients with venous thromboembolism. The pharmacogenomics journal 2018 Aug . Kabalak P?nar Ak?n, Sava? ?smail, Akar Nejat, Demir Nalan, E?in Yon |
| Genetic causes of resistance to vitamin K antagonists in Polish patients: a novel p.Ile123Met mutation in VKORC1 gene. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2018 5 29 (5): 429-434. Wzorek Joanna, Wypasek Ewa, Awsiuk Magdalena, Potaczek Daniel P, Undas Anet |
| Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms. Vascular pharmacology 2018 Feb . Bryk Agata Hanna, Wypasek Ewa, Plens Krzysztof, Awsiuk Magdalena, Undas Anet |
| Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2020 4 26 1076029620909154. Rojo Mario, Roco Angela Margarita, Suarez Marcelo, Lavanderos Maria Alejandra, Verón Gabriel, Bertoglia Maria Paz, Arredondo Annabella, Nieto Elena, Rubilar Juan Carlos, Tamayo Francisca, Cruz Daniela, Muñoz Jessica, Bravo Gabriela, Salas Patricio, Mejías Fanny, Véliz Paulo, Godoy Gerald, Varela Nelson Miguel, Llull G, Quiñones Luis Ab |
| Acenocoumarol Pharmacogenetic Dosing Algorithm versus Usual Care in Patients with Venous Thromboembolism: A Randomised Clinical Trial. Journal of clinical medicine 2021 7 10 (13): . Tong Hoi Yan, Borobia Alberto M, Quintana-Díaz Manuel, Fabra Sara, González-Viñolis Manuel, Fernández-Capitán Carmen, Rodriguez-Dávila María A, Lorenzo Alicia, López-Parra Ana María, Ruiz-Giménez Nuria, Abad-Santos Francisco, Suarez Carmen, Madridano Olga, Gómez-Cerezo Jorge Francisco, Llamas Pilar, Baeza-Richer Carlos, Arroyo-Pardo Eduardo, Carcas Antonio J, The Pgx-Ace Spanish Investigators Grou |
| Effect of NPC1L1 polymorphism on warfarin stable dose in Chinese patients under heart valve replacement surgery. Clinical and experimental pharmacology & physiology 2021 Oct . Ma Siqing, Luo Zhiying, Zhou Xinmin, Zhou Honghao, Chen Ling, Zhang W |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 25, 2023
- Content source: